IDEXX Laboratories, Inc. has announced a new diagnostic test for canine lymphoma, IDEXX Cancer Dx, offering an affordable and accessible method for early cancer detection in dogs. The test, which can be added to regular wellness screenings or diagnostic panels, provides veterinarians with actionable results in just 2–3 days, with prices starting as low as $15.

As per IDEXX’s statement, cancer is a leading cause of death among dogs, with 20 million dogs at higher risk for the disease. Lymphoma, which accounts for nearly a quarter of all new cancer diagnoses in dogs, is one of the most common types. Early detection of lymphoma is crucial as treatment can help extend a dog’s lifespan and improve its quality of life.

IDEXX promises their new test is easy to integrate into existing veterinary workflows and that veterinarians can add it to standard diagnostic panels with just a single blood sample. The results promise valuable insights, including B-cell and T-cell phenotype classifications, at no additional cost when available. IDEXX reports that early data shows the test can detect lymphoma before clinical signs appear, highlighting its potential for use in routine preventive care for at-risk dogs.

The IDEXX Cancer Dx panel will be available in the U.S. and Canada starting in late March 2025.